Start here if you're new
what it is
Sana is trying to turn engineered cells into medicines for cancer, diabetes, brain disease, and rare genetic disorders.
how it gets paid
Last year Sana Biotechnology made n/a in revenue.
what just happened
Fourth-quarter EPS came in at -$0.21, improved from -$0.45 a year earlier.
At a glance
B balance sheet — gets the job done, barely
-$1.16 fy2024 eps est
1.7 beta
~$897M market cap
small cap
xvary composite: 47/100 — below average
What they do
Sana is trying to turn engineered cells into medicines for cancer, diabetes, brain disease, and rare genetic disorders.
Sana's edge is breadth, not cash flow. It has programs across at least 6 disease areas, with 194 employees building one cell-engineering platform. Platform → reusable cell-engineering toolkit → so one scientific win can help more than one program, which matters when you have no product revenue yet.
How they make money
n/a
annual revenue
The products that matter
pre-revenue drug development
Cell & Gene Therapy Pipeline
$0 revenue · entire equity story
it's the whole company today: $0 revenue and a $244.2M trailing loss mean the current valuation rests on future trial data, not a product portfolio.
pipeline only
Key numbers
$1.16
2024 EPS
EPS → profit per share → so a -$1.16 result tells you Sana is still burning cash, not harvesting a product franchise.
$68M
long-term debt
Debt is 7% of capital. Plain English: borrowing exists, but it is not the main thing holding this company up or dragging it down.
1.7
beta
Beta → stock volatility versus the market → so 1.7 means the shares have moved about 70% more than the market.
194
employees
Headcount is small for a company spanning at least 6 disease areas, which shows both focus and how thin resources can get.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $68M (7% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for SANA right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Fourth-quarter EPS came in at -$0.21, improved from -$0.45 a year earlier.
The main takeaway is narrower losses, not sales momentum. Sana still has no reported annual revenue, so the quarter was about cash burn and pipeline survival.
$0.21
eps
n/a
n/a
n/a
n/a
the number that mattered
The key number was -$0.21 in Q4 2024 EPS because it was less than half the prior year's -$0.45 loss, showing expense pressure eased.
source: quarterly EPS history, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The risk picture here is not abstract. Sana has $0 revenue, a $244.2M trailing loss, and less than a year of cash runway — so the top threat is time.
med
cash runway is already under one year
That means financing risk is current, not theoretical. A pre-revenue company cannot out-will a cash balance.
With $0 revenue and a $244.2M trailing loss, fresh capital can become as important as the science itself.
med
clinical disappointment hits 100% of the thesis
There is no commercial business to cushion a bad readout. The entire valuation depends on future data getting better than the market expects.
A setback would pressure all of the current $897M equity story because there is no revenue stream underneath it.
med
the April 8, 2025 Pomerantz investor alert is an added overhang
Legal noise does not decide the science, but it can still weigh on sentiment and management bandwidth.
When investor confidence is already doing the financing work, extra legal uncertainty is not trivial.
med
larger rivals already have commercial muscle
Vertex and Gilead are not waiting around. They have revenue, infrastructure, and more room to absorb failed bets.
Sana does not need to be the only company with good science. It needs to be one of the few that can turn science into something fundable.
At a $897M market cap, you are paying for future data while the current business produces $0 revenue and has less than a year of cash runway.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
cash runway versus burn
The page already tells you the key fact: less than one year of cash runway. If that does not improve, financing risk moves from background noise to the whole soundtrack.
calendar
conference appearances in March 2026
The Cowen 46th Annual Health Care Conference on March 2, 2026 and the Citizens JMP Life Sciences Conference put management in front of investors when the company most needs credibility.
risk
legal overhang from the Pomerantz filing
The April 8, 2025 investor alert is not the operating thesis, but it can still shape sentiment around an already speculative setup.
trend
volatility staying extreme
A 1.7 beta and price stability of 5 / 100 tell you the stock reprices fast. In practice, sentiment can move before fundamentals do.
Analyst rankings
balance sheet grade
B
Adequate balance-sheet quality for a company with no revenue. In human-speak: this is survivable for now, not comfortable.
risk rank
3
Middle-of-the-pack on the underlying risk scale. That sounds calmer than the stock actually trades because clinical-stage volatility does not read like a utility bill.
price stability
5 / 100
Very low stability. Translation: this name can move on headlines, financing assumptions, and trial read-throughs long before it moves on revenue.
xvary composite
47 / 100
Below average overall. The score is not calling the science bad — it is penalizing a setup where cash, volatility, and execution all matter at once.
source: institutional data
Institutional activity
institutional ownership data for SANA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive